¼¼°èÀÇ ºÐÀÚ¼¼Æ÷À¯ÀüÇÐ ½ÃÀå
Molecular Cytogenetics
»óǰÄÚµå : 1770133
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 657 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,222,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,666,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

ºÐÀÚ¼¼Æ÷À¯ÀüÇÐ ¼¼°è ½ÃÀåÀº 2030³â±îÁö 35¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 21¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ºÐÀÚ¼¼Æ÷À¯ÀüÇÐ ¼¼°è ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö CAGR 8.8%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 35¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ¼Ò¸ðǰÀº CAGR 8.9%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 20¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±â±â ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 7.8%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 9¾ï 3,950¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 10.1%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ºÐÀÚ¼¼Æ÷À¯ÀüÇÐ ½ÃÀåÀº 2024³â¿¡ 9¾ï 3,950¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 2¾ï 3,140¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 10.1%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 7.5%¿Í 7.8%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 8.0%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ºÐÀÚ¼¼Æ÷À¯ÀüÇÐ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

ºÐÀÚ¼¼Æ÷À¯ÀüÇÐÀº ºÐÀÚ»ý¹°Çаú ¼¼Æ÷À¯ÀüÇÐÀÌ ±³Â÷ÇÏ´Â ºÐ¾ß·Î ¿°»öü¿Í ±× ±¸Á¶, ±â´É, °Åµ¿À» ºÐÀÚ ¼öÁØ¿¡¼­ ¿¬±¸ÇÏ´Â µ¥ ÃÊÁ¡À» ¸ÂÃß°í ÀÖ½À´Ï´Ù. ÀÌ °úÇÐ ºÐ¾ß¿¡¼­´Â ¿°»öü ÀÌ»ó°ú À¯ÀüÀû º¯À̸¦ ºÐ¼®Çϱâ À§ÇØ ´Ù¾çÇÑ ±â¼úÀ» »ç¿ëÇÕ´Ï´Ù. ºÐÀÚ¼¼Æ÷À¯ÀüÇп¡¼­ »ç¿ëµÇ´Â ÁÖ¿ä µµ±¸·Î´Â Çü±¤ in situ hybridization(FISH), ºñ±³ À¯Àüü ÇÏÀ̺긮µåÈ­(CGH), ¾î·¹ÀÌ CGH µîÀÌ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀ» ÅëÇØ À¯Àü¹°ÁúÀÇ »ó¼¼ÇÑ °Ë»ç°¡ °¡´ÉÇϸç, °á½Ç, Áߺ¹, ÀüÁ ¹× ±âŸ ¿°»öü Àç¹è¿­À» Á¤È®ÇÏ°Ô ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. ºÐÀÚ¼¼Æ÷À¯ÀüÇÐÀº À¯Àü¼º ÁúȯÀÇ Áø´Ü, ¾Ï Ä¡·á Áöħ, »êÀü ¼±º°°Ë»ç¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.

ÃÖ±Ù ºÐÀÚ¼¼Æ÷À¯ÀüÇÐ ºÐ¾ß´Â ±â¼ú ¹× ¹æ¹ý·ÐÀÇ Çâ»óÀ¸·Î Å« ¹ßÀüÀ» ÀÌ·ç¾ú½À´Ï´Ù. ÇÏÀ̽º·çDz ½ÃÄö½Ì ±â¼úÀº À¯ÀüÀÚ ÀÌ»óÀ» °ËÃâÇÏ´Â ´É·Â¿¡ Çõ¸íÀ» °¡Á®¿ÔÀ¸¸ç, ±× ¾î´À ¶§º¸´Ù Æ÷°ýÀûÀ̰í Á¤È®ÇÑ µ¥ÀÌÅ͸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½ºÀÇ ÅëÇÕÀº º¹ÀâÇÑ À¯Àü Á¤º¸ÀÇ ºÐ¼®°ú ÇØ¼®À» ´õ¿í °­È­Çß½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀ¸·Î ºÐÀÚ¼¼Æ÷À¯ÀüÇÐÀÇ ÀÀ¿ë ¹üÀ§°¡ ±âÁ¸ ºÐ¾ß ¿Ü¿¡µµ È®´ëµÇ¾î ÁøÈ­»ý¹°ÇÐ, Áý´ÜÀ¯ÀüÇÐ, °³ÀθÂÃãÀÇ·á µîÀÇ ¿¬±¸°¡ ¿ëÀÌÇØÁ³½À´Ï´Ù. ÀÓ»ó¿¡¼­ ºÐÀÚ¼¼Æ÷À¯ÀüÇÐÀº ´Ù¾çÇÑ ¾Ï°ú °ü·ÃµÈ ƯÁ¤ À¯ÀüÀÚ ¸¶Ä¿¸¦ ã¾Æ³»¾î ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±ÇÏ´Â ¸ÂÃãÇü Ä¡·á Àü·«À» ¼ö¸³ÇÏ´Â µ¥ ÇʼöÀûÀÎ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.

ºÐÀÚ¼¼Æ÷À¯ÀüÇÐ ½ÃÀåÀÇ ¼ºÀåÀº ±â¼ú Çõ½Å, À¯Àü¼º Áúȯ ¹× ¾ÏÀÇ À¯º´·ü Áõ°¡, ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. Â÷¼¼´ë ½ÃÄö¼­ ¹× ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ±â¼úÀÇ ¹ßÀüÀ¸·Î À¯ÀüÀÚ °Ë»çÀÇ Á¤È®¼º, ¼Óµµ, ºñ¿ë È¿À²¼ºÀÌ Å©°Ô Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·Î ÀÎÇØ ÀÏ»óÀûÀÎ ÀÓ»ó Áø´Ü¿¡¼­ °í±Þ Á¶»ç ¿¬±¸¿¡ À̸£±â±îÁö º¸´Ù ±¤¹üÀ§ÇÏ°í ½Ç¿ëÀûÀÎ ¿ëµµ·Î »ç¿ëÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ, Ä¡·á¹ýÀ» Á¶Á¤Çϱâ À§ÇØ À¯ÀüÀÚ Á¤º¸¿¡ Å©°Ô ÀÇÁ¸ÇÏ´Â ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ Àνİú äÅÃÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÇコÄɾî ÀÎÇÁ¶óÀÇ È®´ë¿Í °ø°ø ¹× ¹Î°£ ºÎ¹®ÀÇ À¯ÀüÀÚ ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÅõÀÚ È®´ëµµ ½ÃÀåÀ» °­È­½Ã۰í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀº »õ·Î¿î ±â¼ú ¹× ÀÀ¿ë ºÐ¾ßÀÇ Áö¼ÓÀûÀÎ °³¹ß°ú ÇÔ²² ºÐÀÚ¼¼Æ÷À¯ÀüÇÐ ºÐ¾ßÀÇ ¿ªµ¿ÀûÀÎ ÁøÈ­¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

±¸¼º¿ä¼Ò(¼Ò¸ðǰ, ±â±â, ¼ÒÇÁÆ®¿þ¾î ¹× ¼­ºñ½º), Å×Å©´Ð(CGH, FISH, ¸é¿ªÁ¶Á÷È­ÇÐ, ÇÙÇü ºÐ¼®, ±âŸ Å×Å©´Ð), ¿ëµµ(À¯ÀüÁúȯ, ¾Ï, ¸ÂÃãÇü ÀÇ·á, ±âŸ ¿ëµµ), ÃÖÁ¾ ¿ëµµ(ÀÓ»ó ¹× ¿¬±¸¼Ò, Á¦¾à ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷, Çмú¿¬±¸±â°ü, ±âŸ ÃÖÁ¾ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM ¹× ¾÷°èº° SLM Äõ¸®¸¦ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Molecular Cytogenetics Market to Reach US$3.5 Billion by 2030

The global market for Molecular Cytogenetics estimated at US$2.1 Billion in the year 2024, is expected to reach US$3.5 Billion by 2030, growing at a CAGR of 8.8% over the analysis period 2024-2030. Consumables, one of the segments analyzed in the report, is expected to record a 8.9% CAGR and reach US$2.0 Billion by the end of the analysis period. Growth in the Instruments segment is estimated at 7.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$939.5 Million While China is Forecast to Grow at 10.1% CAGR

The Molecular Cytogenetics market in the U.S. is estimated at US$939.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$231.4 Million by the year 2030 trailing a CAGR of 10.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.5% and 7.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.0% CAGR.

Global Molecular Cytogenetics Market - Key Trends & Drivers Summarized

Molecular cytogenetics is a field at the intersection of molecular biology and cytogenetics, focusing on the study of chromosomes and their structure, function, and behavior at a molecular level. This branch of science employs various techniques to analyze chromosomal abnormalities and genetic variations that can lead to diseases. Among the primary tools used in molecular cytogenetics are fluorescence in situ hybridization (FISH), comparative genomic hybridization (CGH), and array CGH. These technologies allow for the detailed examination of genetic material, identifying deletions, duplications, translocations, and other chromosomal rearrangements with high precision. Molecular cytogenetics plays a crucial role in diagnosing genetic disorders, guiding cancer treatment, and conducting prenatal screening.

Over recent years, the field of molecular cytogenetics has advanced significantly, driven by improvements in technology and methodologies. High-throughput sequencing techniques have revolutionized the ability to detect genetic anomalies, providing more comprehensive and accurate data than ever before. The integration of bioinformatics has further enhanced the analysis and interpretation of complex genetic information. These advancements have expanded the applications of molecular cytogenetics beyond traditional areas, facilitating research in evolutionary biology, population genetics, and personalized medicine. In clinical settings, molecular cytogenetics has become indispensable for identifying specific genetic markers associated with various cancers, enabling tailored treatment strategies that improve patient outcomes.

The growth in the molecular cytogenetics market is driven by several factors, including technological innovations, the rising prevalence of genetic disorders and cancers, and increasing demand for personalized medicine. Advances in next-generation sequencing and microarray technologies have significantly improved the accuracy, speed, and cost-effectiveness of genetic testing. This has made molecular cytogenetics more accessible and practical for a wider range of applications, from routine clinical diagnostics to advanced research studies. The increasing awareness and adoption of personalized medicine, which relies heavily on genetic information to tailor treatments, has also fueled market growth. Additionally, the expansion of healthcare infrastructure and growing investments in genetic research and development by both public and private sectors have bolstered the market. These factors, combined with the continuous development of new techniques and applications, are driving the dynamic evolution of the molecular cytogenetics field.

SCOPE OF STUDY:

The report analyzes the Molecular Cytogenetics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Component (Consumables, Instruments, Software & Services); Technique (CGH, FISH, Immunohistochemistry, Karyotyping, Other Techniques); Application (Genetic Disorders, Cancer, Personalized Medicine, Other Applications); End-Use (Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes, Other End-Uses)

Geographic Regions/Countries:

World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Spain; Russia; Rest of Europe; Asia-Pacific; Australia; India; South Korea; Rest of Asia-Pacific; Latin America; Argentina; Brazil; Mexico; Rest of Latin America; Middle East; Iran; Israel; Saudi Arabia; UAE; Rest of Middle East; Africa.

Select Competitors (Total 44 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â